Journal
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
Volume 12, Issue 3, Pages 405-434Publisher
AMER SCIENTIFIC PUBLISHERS
DOI: 10.1166/jbn.2016.2157
Keywords
Dendritic Cells; In Vivo Modulation; Nanotechnology Systems; Cancer Vaccine Clinical Trials; Tumor Associated Antigens
Funding
- Fundacao para a Ciencia e a Tecnologia, Ministerio da Ciencia e da Tecnologia, Portugal [PTDC/SAU-FAR/119389/2010, Pest-OE/SAU/UI4013/2011]
- Fundação para a Ciência e a Tecnologia [PTDC/SAU-FAR/119389/2010] Funding Source: FCT
Ask authors/readers for more resources
In preceding decades, different mechanisms have been proposed to instruct dendritic cells (DCs) to induce immune responses against tumor antigens (TAs), thus breaking immune tolerance. Immunotherapy has been, for the last two decades, an attractive and promising therapeutic approach to fight cancer. This review will approach the nature of the immune response during cancer development and its correlation with DC function, as well as cancer vaccine principles and limitations. An overview of several delivery strategies used for in vivo modulation of DCs and direct activation of T cells will be provided, highlighting their advantages, limitations, and optimization strategies. This manuscript also presents a critical and systematic review of recent clinical trials that are investigating the therapeutic effect of these approaches, discussing prognostic outcomes of combined-treatment modalities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available